The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
KRAS wild-type pancreatic ductal adenocarcinoma: Molecular and therapeutic opportunities.
 
Aakash Desai
No Relationships to Disclose
 
Daniel Walden
No Relationships to Disclose
 
Thorvardur Ragnar Halfdanarson
Consulting or Advisory Role - Advanced Accelerator Applications (Inst); Crinetics Pharmaceuticals (Inst); Ipsen (Inst); ITM Isotope Technologies Munich (Inst); Tersera; TERUMO; Viewpoint Molecular Targeting (Inst)
Research Funding - Advanced Accelerator Applications (Inst); Agios (Inst); Basilea (Inst); Ipsen (Inst); Novartis (Inst); Thermo Fisher Scientific (Inst); Turnstone Bio (Inst)
 
Steven R Alberts
No Relationships to Disclose
 
Robert R. McWilliams
Stock and Other Ownership Interests - Zentalis
Consulting or Advisory Role - Zentalis
Research Funding - Bristol-Myers Squibb (Inst); GlaxoSmithKline/Tesaro (Inst); Merck (Inst); Newlink Genetics (Inst)
 
Amit Mahipal
No Relationships to Disclose
 
Daniel H. Ahn
Stock and Other Ownership Interests - Natera
Consulting or Advisory Role - Advanced Accelerator Applications; Daiichi Sankyo/Astra Zeneca; Eisai; Exelixis; Genentech/Roche; Novartis
Research Funding - AstraZeneca; Bayer
 
Hani M. Babiker
Consulting or Advisory Role - Celgene; Endocyte; Idera; Myovant Sciences; Novocure
Speakers' Bureau - Guardant Health
 
Sri Harsha Tella
No Relationships to Disclose
 
Patrick Walsh McGarrah
No Relationships to Disclose
 
Sani Haider Kizilbash
Research Funding - Apollomics (Inst); Celgene (Inst); Incyte (Inst); Loxo (Inst); Nerviano Medical Sciences (Inst); Orbus Therapeutics (Inst); Wayshine Biopharma (Inst)
 
Alex A. Adjei
Research Funding - Bayer Schering Pharma (Inst); I-Mab (Inst); Jacobio (Inst); Kura Oncology (Inst); Merck KGaA (Inst); Tesaro (Inst); Zai Lab (Inst)
(OPTIONAL) Uncompensated Relationships - Merck KGaA; Swiss Rockets; Zai Lab
 
Tanios S. Bekaii-Saab
Consulting or Advisory Role - Abbvie; Amgen (Inst); Arcus Biosciences (Inst); AstraZeneca; Bayer (Inst); BeiGene; Boehringer Ingelheim; Celularity; Daiichi Sankyo/UCB Japan; Deciphera; Eisai; Eisai; Exact Sciences; Foundation Medicine; Foundation Medicine; Illumina; Immuneering; Incyte (Inst); Ipsen (Inst); Janssen; Kanaph Therapeutics; Lilly (Inst); Natera; Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst); SOBI; Stemline Therapeutics; Treos Bio
Patents, Royalties, Other Intellectual Property - Patent WO/2018/183488; Patent WO/2019/055687
Other Relationship - 1Globe Health Institute; AstraZeneca; Exelixis; FibroGen; Imugene; Lilly; Merck (Inst); Pancreatic Cancer Action Network; Replimune; Sun Biopharma; Suzhou Kintor Pharmaceuticals; UpToDate; Xilis
 
Wen Wee Ma
Research Funding - Actuate Therapeutics (Inst); Athenex (Inst); BioMed Valley Discoveries (Inst); Bristol-Myers Squibb (Inst); Cardiff Oncology (Inst); Elucida Oncology (Inst); Genentech (Inst); Ipsen (Inst); Jacobio (Inst); Sun Pharma (Inst)